Back to Top

Our motivation

The World Health Organisation (WHO) estimates that more than one billion people worldwide are suffering from diseases of the Central Nervous System (CNS). MS is an inflammatory, demyelinating disease and the leading cause of non-traumatic neurological disability in young adults. MS is estimated to affect 2.3 million people worldwide; prevalence is particularly high in Europe and North America, with rates over 100 cases per 100,000.

Current standard therapies of MS include anti-inflammatory and symptomatic treatments. Although, relapse occurrence and duration are reduced by means of these therapies, no regeneration is achieved and there are no treatments for the progressive forms of MS. Therefore, MS is still a degenerative disease that leads to disability of patients in their most productive years.

Read more

One innovation, multiple fields of application

The technology developed by the N2B-Patch Project may also be suitable for the use of different pharmaceutical ingredients.

The envisaged direct drug delivery platform may also support the treatment of other demyelinating disorders and other central nervous system indications, e.g. stroke, neurodegenerative diseases or tumours.

The scale-up and Good Manufacturing Practice (GMP) utilised during the development of this drug delivery platform may also be exploited to reduce time and cost to market and to also provide wider options to the patient.


Our approach

The project addresses the development of an innovative, biomaterial-based galenic formulation in combination with a medical device for the treatment of MS. N2B-patch has the potential to bypass the Blood Brain Barrier and to deliver the biomolecules as active pharmaceutical ingredient API to the Central Nervous System.


The N2B-patch project will deliver 3 outputs:

  • An Ensemble composed of biomaterial-based drug particles and an innovative Active Pharmaceutical Ingredient API (biomolecules) for MS treatment:



  • The hydrogel formulation as a minimally-invasive carrier:



  • The applicator device as integral part of the functional and minimally-invasive system:

Don't have an account yet? Register Now!

Sign in to your account